Apixaban

Green-G

Brand Name(s):Eliquis

Indication:Stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (prevention of). DVT & or Pulmonary Embolism, treatment & prevention.

Rationale:

Considered:Jan-13

Review Date:Nov-24

Comments:
SPC update; SPCs state that for situations when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding, a reversal agent for factor Xa inhibitors is now available (andexanet alfa)…………………………
Rivaroxaban is the first line formulary choice of DOAC for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE Refer to Formulary Guidelines:
Apixaban is the first line formulary choice of DOAC for patients with Non Valvular AF
…………………………
Drug Safety Update
Direct-acting oral anticoagulants (DOACs): increased risk of recurrent thrombotic events in patients with antiphospholipid syndrome
June 19
…………………………

NICE CG 180 The Management of AF: Information can be found at:http://www.nice.org.uk/guidance/CG180
June 2014
…………………………
Risk of haemorrhage
Prescribers should note guidance issued by MHRA regarding risk of serious haemorrhage with the new oral anticoagulant drugs (NOAC’s). Guidance contains updated information on contraindications and warnings for use.

MHRA guidance available at: http://www.mhra.gov.uk/home/groups/pl-p/documents/drugsafetymessage/con321961.pdf
Issued October 2013
…………………………